Applied Research, PINC AI Applied Sciences, Premier Inc., Charlotte, NC, United States of America.
Value Evidence & Outcomes, GSK, Collegeville, PA, United States of America.
PLoS One. 2022 Nov 21;17(11):e0277713. doi: 10.1371/journal.pone.0277713. eCollection 2022.
We evaluated associations between antibiotic prescription and healthcare resource use and costs (Part A), and between antibiotic switching and healthcare resource use, costs, and uncomplicated urinary tract infection recurrence (Part B) in female patients with uncomplicated urinary tract infection in the United States.
This retrospective cohort study of linked Optum and Premier Healthcare Database data included female patients ≥12 years old with an uncomplicated urinary tract infection diagnosis (index date), who were prescribed antibiotics during an outpatient/emergency department visit between January 1, 2013 and December 31, 2018. In Part A, patients were stratified by antibiotic prescription appropriateness: appropriate and optimal (compliant with Infectious Diseases Society of America 2011 guidelines for drug class/treatment duration) versus inappropriate/suboptimal (inappropriate drug class/treatment duration per Infectious Diseases Society of America 2011 guidelines, and/or treatment failure). In Part B, patients were stratified by treatment pattern (antibiotic switch vs no antibiotic switch). Healthcare resource use and costs during index episode (within 28 days of index date) and 12-month follow-up were compared.
Of 5870 patients (mean age 44.5 years), 2762 (47.1%) had inappropriate/suboptimal prescriptions and 567 (9.7%) switched antibiotic. Inappropriate/suboptimal prescriptions were associated with higher healthcare resource use (mean number of ambulatory care and pharmacy claims [both p < 0.001]), and higher total mean cost (inpatient, outpatient/emergency department, ambulatory visits, and pharmacy costs) per patient ($2616) than appropriate and optimal prescriptions ($649; p < 0.001) (Part A). Antibiotic switching was associated with more pharmacy claims and higher total mean costs (p ≤ 0.01), and a higher incidence of recurrent uncomplicated urinary tract infection (18.9%) than no antibiotic switching (14.2%; p < 0.001) (Part B).
Inappropriate/suboptimal prescriptions and antibiotic switching were associated with high costs, ambulatory care, and pharmacy claims, suggesting a need for improved uncomplicated urinary tract infection prescribing practices in the United States.
我们评估了美国女性单纯性尿路感染患者中抗生素处方与医疗资源使用和成本之间的关系(第 A 部分),以及抗生素转换与医疗资源使用、成本和单纯性尿路感染复发之间的关系(第 B 部分)。
这项回顾性队列研究使用了 Optum 和 Premier Healthcare Database 数据库中的数据,包括在 2013 年 1 月 1 日至 2018 年 12 月 31 日期间,在门诊/急诊就诊期间接受过抗生素治疗的 12 岁以上女性单纯性尿路感染患者(索引日期)。在第 A 部分中,根据抗生素处方的适当性将患者分层:适当和最佳(符合 2011 年传染病学会美国药物类别/治疗持续时间指南)与不适当/次优(根据 2011 年传染病学会美国指南,药物类别/治疗持续时间不适当,和/或治疗失败)。在第 B 部分中,根据治疗模式(抗生素转换与无抗生素转换)将患者分层。比较索引期(索引日期后 28 天内)和 12 个月随访期间的医疗资源使用和成本。
在 5870 名患者(平均年龄 44.5 岁)中,2762 名(47.1%)患者的处方不适当/次优,567 名(9.7%)患者抗生素转换。不适当/次优的处方与更高的医疗资源使用(门诊护理和药房索赔的平均数量[均 p < 0.001])和更高的每位患者平均总成本(住院、门诊/急诊、门诊就诊和药房费用)相关(2616 美元),而适当和最佳的处方(649 美元;p < 0.001)(第 A 部分)。抗生素转换与更多的药房索赔和更高的总成本(p ≤ 0.01)相关,并且单纯性尿路感染复发的发生率(18.9%)高于无抗生素转换(14.2%)(p < 0.001)(第 B 部分)。
不适当/次优的处方和抗生素转换与高成本、门诊护理和药房索赔相关,这表明美国需要改进单纯性尿路感染的处方实践。